Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Sionna Therapeutics, Inc. (SION)

Sionna Therapeutics Q3 net loss widens to $32.4 million; workforce cut about 46%

Negative Impact 4 of 5 earnings

Sionna Therapeutics reported a third-quarter 2026 net loss of $32.4 million, up from $20.3 million a year earlier, as research and development and general and administrative expenses rose. The company cut its workforce by about 46% in September 2026 and is not advancing SION-719 after its PreciSION CF Phase 2a trial missed its key activity endpoint, focusing instead on SION-451 + SION-2222, with a Phase 2 trial planned for the first quarter of 2027. Cash, cash equivalents and marketable securities were $249.8 million at September 30, 2026, which the company expects to fund operations into the second half of 2029.

Key points

  • Net loss was $32.4 million, or $0.72 per share, for the quarter ended September 30, 2026, compared with $20.3 million, or $0.46 per share, a year earlier.
  • R&D expenses were $22.0 million and G&A expenses were $12.8 million, up from $16.0 million and $7.8 million in the prior-year quarter.
  • Cash, cash equivalents and marketable securities totaled $249.8 million, down from $310.3 million at December 31, 2025.
  • The AscenSION CF Phase 2 proof-of-concept trial of SION-451 + SION-2222 is expected to start in the first quarter of 2027.

The filing

CompanySionna Therapeutics, Inc. (SION)
Form8-K, current report
Filed with the SECNov 10, 2026, 7:05 AM ET
Accession number0001628280-26-072497

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 7:11 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.